IL121565A - Stabilized pharmaceutical preparations containing derivatives of acid (E) -3,5-DIHYDROXY-7- [4 (-4) -FLUOROPHENYL-2 (CYCLOPROPYL-QUINOLIN-3 (-YL] -6-HEPTENOIC - Google Patents

Stabilized pharmaceutical preparations containing derivatives of acid (E) -3,5-DIHYDROXY-7- [4 (-4) -FLUOROPHENYL-2 (CYCLOPROPYL-QUINOLIN-3 (-YL] -6-HEPTENOIC

Info

Publication number
IL121565A
IL121565A IL12156596A IL12156596A IL121565A IL 121565 A IL121565 A IL 121565A IL 12156596 A IL12156596 A IL 12156596A IL 12156596 A IL12156596 A IL 12156596A IL 121565 A IL121565 A IL 121565A
Authority
IL
Israel
Prior art keywords
pharmaceutical composition
composition
dihydroxy
quinolin
cyclopropyl
Prior art date
Application number
IL12156596A
Other languages
English (en)
Hebrew (he)
Other versions
IL121565A0 (en
Inventor
Muramatsu Toyojiro
Mashita Katsumi
Shinoa Yasuo
Sassa Hironori
Kawashima Hiroyuki
Tanizawa Yoshio
Takeuchi Hideatsu
Original Assignee
Kowa Co
Nissan Chemical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co, Nissan Chemical Ind Ltd filed Critical Kowa Co
Publication of IL121565A0 publication Critical patent/IL121565A0/xx
Publication of IL121565A publication Critical patent/IL121565A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL12156596A 1995-12-22 1996-12-20 Stabilized pharmaceutical preparations containing derivatives of acid (E) -3,5-DIHYDROXY-7- [4 (-4) -FLUOROPHENYL-2 (CYCLOPROPYL-QUINOLIN-3 (-YL] -6-HEPTENOIC IL121565A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP35465495 1995-12-22
PCT/JP1996/003722 WO1997023200A1 (en) 1995-12-22 1996-12-20 Pharmaceutical composition stabilized with a basic agent

Publications (2)

Publication Number Publication Date
IL121565A0 IL121565A0 (en) 1998-02-08
IL121565A true IL121565A (en) 2002-02-10

Family

ID=18439011

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12156596A IL121565A (en) 1995-12-22 1996-12-20 Stabilized pharmaceutical preparations containing derivatives of acid (E) -3,5-DIHYDROXY-7- [4 (-4) -FLUOROPHENYL-2 (CYCLOPROPYL-QUINOLIN-3 (-YL] -6-HEPTENOIC

Country Status (26)

Country Link
EP (1) EP0814782B1 (zh)
JP (1) JP3276962B2 (zh)
KR (1) KR100348842B1 (zh)
CN (1) CN1137684C (zh)
AT (1) ATE228354T1 (zh)
AU (1) AU725622B2 (zh)
CA (1) CA2213608C (zh)
CZ (1) CZ288545B6 (zh)
DE (2) DE122011000014I1 (zh)
DK (1) DK0814782T3 (zh)
ES (1) ES2183023T3 (zh)
FR (1) FR11C0007I2 (zh)
HU (1) HU227798B1 (zh)
IL (1) IL121565A (zh)
MX (1) MX9706389A (zh)
NO (2) NO316724B1 (zh)
NZ (1) NZ324446A (zh)
PL (1) PL186907B1 (zh)
PT (1) PT814782E (zh)
RU (1) RU2142790C1 (zh)
SI (1) SI0814782T1 (zh)
SK (1) SK282991B6 (zh)
TW (1) TW436294B (zh)
UA (1) UA29513C2 (zh)
WO (1) WO1997023200A1 (zh)
ZA (1) ZA9610792B (zh)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO5140079A1 (es) * 1998-10-14 2002-03-22 Novartis Ag Composicion farmaceutica de liberacion sostenida y metodo para liberar un agente farmaceuticamente activo de liberacion sostenida y metodo para liberar un agente far- maceuticamente activo
SI20109A (sl) * 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
JP2002538202A (ja) * 1999-03-08 2002-11-12 メルク エンド カムパニー インコーポレーテッド ＨＭＧ−ＣｏＡレダクターゼ阻害剤のジヒドロキシオープンアシッド及びその塩
US6569461B1 (en) 1999-03-08 2003-05-27 Merck & Co., Inc. Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
EP1036563A1 (en) * 1999-03-08 2000-09-20 MERCK & CO. INC. Delayed-release oral formulation of dihydroxy open acid simvastatin and salts and esters thereof
WO2001042218A1 (fr) * 1999-12-13 2001-06-14 Kabushiki Kaisha Toyota Chuo Kenkyusho Derives de quinoleine et dispositifs electroluminescents organiques
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
USRE44578E1 (en) 2000-04-10 2013-11-05 Teva Pharmaceutical Industries, Ltd. Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
US6242003B1 (en) 2000-04-13 2001-06-05 Novartis Ag Organic compounds
WO2001093860A1 (en) 2000-06-09 2001-12-13 Lek Pharmaceuticals D.D. Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
US6806290B2 (en) 2000-06-09 2004-10-19 Lek Pharmaceuticals D.D. Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
US20060127474A1 (en) 2001-04-11 2006-06-15 Oskar Kalb Pharmaceutical compositions comprising fluvastatin
TW200404544A (en) * 2002-06-17 2004-04-01 Kowa Co Controlled release pharmaceutical composition
AU2003264443A1 (en) * 2002-09-20 2004-04-08 Kowa Co., Ltd. Preparation for external use
AR041089A1 (es) 2003-05-15 2005-05-04 Merck & Co Inc Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
EP1699760B1 (en) 2003-12-23 2017-05-17 Merck Sharp & Dohme Corp. Anti-hypercholesterolemic compounds
ATE535614T1 (de) 2003-12-30 2011-12-15 Kowa Co Screening-verfahren fuer gamma-sekretase- inhibitoren
SE0400235D0 (sv) * 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
US8314124B2 (en) 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
EP1719524B1 (en) 2004-02-25 2014-11-26 Kowa Company, Ltd. Nuclear transfer promoter for rac protein and method of screening the same
WO2005079847A1 (ja) 2004-02-25 2005-09-01 Kowa Company, Ltd. Cdc42タンパク質の核内移行促進剤及びそのスクリーニング方法
US20060211752A1 (en) 2004-03-16 2006-09-21 Kohn Leonard D Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
AU2006204038A1 (en) 2005-01-06 2006-07-13 Merck & Co., Inc. Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders
EP1726962A1 (en) * 2005-05-24 2006-11-29 Leiden University Medical Center Apolipoprotein E plasma levels for monitoring and reducing the risk of cardiovascular disease
CN101103983B (zh) * 2006-07-14 2012-09-26 海南盛科生命科学研究院 一种用碱试剂稳定的含匹伐他汀钙的药用组合物及制备工艺
EP2170065A4 (en) 2007-06-20 2011-11-23 Merck Sharp & Dohme DIPHENYL SUBSTITUTED ALKANES
US8372877B2 (en) 2010-04-16 2013-02-12 Cumberland Pharmaceuticals Stabilized statin formulations
KR20130137623A (ko) 2010-10-06 2013-12-17 고쿠리츠다이가쿠호우진 도쿄다이가쿠 림프 부종 예방 치료제
ES2618812T3 (es) 2011-01-20 2017-06-22 Merck Sharp & Dohme Corp. Antagonistas del receptor mineralocorticoide
JP5988963B2 (ja) * 2011-04-12 2016-09-07 沢井製薬株式会社 ピタバスタチン含有製剤及びその製造方法
US9487506B2 (en) 2011-04-13 2016-11-08 Merck Sharp & Dohme Corp. Mineralocorticoid receptor antagonists
WO2012153181A1 (en) 2011-05-11 2012-11-15 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical composition comprising pitavastatin or its pharmaceutically acceptable salts
CN102861018A (zh) * 2011-07-05 2013-01-09 南京长澳医药科技有限公司 一种匹伐他汀钙制剂及其制备工艺
JP5809467B2 (ja) * 2011-07-12 2015-11-11 エルメッド エーザイ株式会社 ピタバスタチン含有組成物及びその製造方法
JP5844574B2 (ja) * 2011-08-10 2016-01-20 共和薬品工業株式会社 ピタバスタチンを含有する安定化された薬物組成物
EP2765859B1 (en) 2011-10-13 2017-01-18 Merck Sharp & Dohme Corp. Mineralocorticoid receptor antagonists
EP3124017A1 (en) 2012-08-08 2017-02-01 Kowa Company, Ltd. Pharmaceutical composition comprising pitavastatine
CN102885797A (zh) * 2012-10-29 2013-01-23 福州海王福药制药有限公司 一种含匹伐他汀钙的组合物及其制备方法和应用
WO2015066490A1 (en) 2013-10-31 2015-05-07 Ohio University Prevention and treatment of non-alcoholic fatty liver disease
EP3148587B1 (en) 2014-05-30 2021-02-24 Pfizer Inc Carbonitrile derivatives as selective androgen receptor modulators
CN106659714B (zh) 2014-07-18 2021-06-08 俄亥俄大学 用于改变生物信号传导的咪唑和噻唑组合物
CN105343008A (zh) * 2015-12-15 2016-02-24 青岛华之草医药科技有限公司 一种匹伐他汀钙组合物
CN107913257A (zh) * 2016-10-10 2018-04-17 北京阜康仁生物制药科技有限公司 一种包含瑞舒伐他汀钙的药物组合物及其制备方法
JP6937195B2 (ja) * 2017-09-01 2021-09-22 興和株式会社 医薬組成物
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1327010C (en) * 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
CA1336714C (en) * 1987-08-20 1995-08-15 Yoshihiro Fujikawa Quinoline type mevalonolactone inhibitors of cholesterol biosynthesis
US5030447A (en) * 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
JP3528186B2 (ja) * 1991-06-24 2004-05-17 日産化学工業株式会社 光学活性キノリンメバロン酸のジアステレオマー塩
HU9203780D0 (en) * 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them

Also Published As

Publication number Publication date
CN1189098A (zh) 1998-07-29
CA2213608C (en) 2003-07-08
WO1997023200A1 (en) 1997-07-03
RU2142790C1 (ru) 1999-12-20
JP3276962B2 (ja) 2002-04-22
SK116097A3 (en) 1998-03-04
EP0814782A1 (en) 1998-01-07
NO973814D0 (no) 1997-08-19
NO2011006I2 (no) 2012-10-01
DE69625046T2 (de) 2003-04-10
KR19980702370A (ko) 1998-07-15
DK0814782T3 (da) 2002-12-16
PL321868A1 (en) 1997-12-22
KR100348842B1 (ko) 2002-12-31
MX9706389A (es) 1998-08-30
NO973814L (no) 1997-10-13
DE122011000014I1 (de) 2011-11-03
SI0814782T1 (en) 2003-04-30
UA29513C2 (uk) 2000-11-15
HUP9903536A2 (hu) 2000-03-28
NO2011006I1 (no) 2011-06-06
SK282991B6 (sk) 2003-01-09
PL186907B1 (pl) 2004-03-31
JPH11503763A (ja) 1999-03-30
ZA9610792B (en) 1997-07-09
FR11C0007I2 (fr) 2012-03-16
NO316724B1 (no) 2004-04-19
EP0814782B1 (en) 2002-11-27
ATE228354T1 (de) 2002-12-15
TW436294B (en) 2001-05-28
IL121565A0 (en) 1998-02-08
CN1137684C (zh) 2004-02-11
HUP9903536A3 (en) 2001-06-28
AU725622B2 (en) 2000-10-19
PT814782E (pt) 2003-04-30
ES2183023T3 (es) 2003-03-16
HU227798B1 (en) 2012-03-28
CZ268197A3 (cs) 1998-05-13
CA2213608A1 (en) 1997-07-03
CZ288545B6 (cs) 2001-07-11
FR11C0007I1 (zh) 2011-04-22
NZ324446A (en) 1999-08-30
DE69625046D1 (de) 2003-01-09
AU1171597A (en) 1997-07-17

Similar Documents

Publication Publication Date Title
EP0814782B1 (en) Pharmaceutical composition stabilized with a basic agent
RU2206324C1 (ru) Фармацевтические композиции, содержащие ингибитор hmg редуктазы
RU2121835C1 (ru) Фармацевтическая композиция
US6465477B1 (en) Stable pharmaceutical composition
AU743043B2 (en) Pharmaceutical preparations of cilansetron stabilized against racemization
EP0952823B1 (en) Stabilized pharmaceutical compositions and process for the preparation thereof
KR20110092804A (ko) 피타바스타틴 칼슘염을 함유하는 약학 조성물
US5091191A (en) Pharmaceutical composition with improved dissolution property
RU2287328C2 (ru) Твердый препарат с высоким всасыванием
JPH08325142A (ja) ヨウ化イソプロパミド含有製剤
WO2010140992A1 (en) Stable pharmaceutical compositions containing rosuvastatin calcium
JP2004010501A (ja) 固形製剤及びその製造方法

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired